Nuts and Seeds Consumption Mitigates Mortality Risk in MAFLD: A Comprehensive Cohort Analysis with Optimal Intake Insights

Author:

Chen Zhanjun1ORCID,Yan Yuqin1,Liu Jinhuang2,Zheng Jianzhong2,Huang Bo2,Huang Dongling2,Lin Jianshan2

Affiliation:

1. The Second Affiliated Hospital of Shenzhen University: Shenzhen Baoan District People's Hospital

2. shenzhen shi baoan qu renmin yiyuan: Shenzhen Baoan District People's Hospital

Abstract

Abstract Background Recently, the designation "Metabolic Associated Fatty Liver Disease" (MAFLD) has emerged to more holistically depict the disease's multifaceted nature. Within this framework, patients are stratified as either metabolically healthy (MH) or metabolically unhealthy (MU). The unique nutrient composition of nuts and seeds (NUTSDS) suggests potential health advantages, potentially mitigating premature mortality risks.This research delves into the impact of NUTSDS consumption on all-cause mortality within the diverse MAFLD categories. Methods We embarked on a prospective cohort investigation involving 13,762 participants, drawn from a nationally representative pool of the National Health and Nutrition Examination Survey. Mortality events and underlying causes were tracked through a linkage with death records until December 31, 2019. To elucidate the connection between NUTSDS intake and mortality across MAFLD categories, we employed both the Weighted Cox proportional hazards regression and Restricted Cubic Spline (RCS) analytical methods.The robustness of our results is further buttressed by a series of stratified and sensitivity assessments. Results Out of the 13,762 studied participants, representing a weighted national estimate of 58,212,532individuals, 62.73% were MAFLD-diagnosed. Among them, 7.79% were MH-MAFLD, and 54.95% were MU-MAFLD. Over 135,552.9 person-years (median follow-up of 9.58 years), there were 1,558 recorded deaths. The fully adjusted Cox model demonstrated a 15% reduced risk of all-cause mortality with NUTSDS intake (HR, 0.85; 95%CI, 0.74–0.97) in the MAFLD group and a similar risk reduction in the MU-MAFLD group (HR, 0.86; 95%CI, 0.76–0.98). Notably, no such associations were found in the Non-MAFLD and MH-MAFLD groups. RCS analyses suggested a U-shaped mortality curve with optimal NUTSDS consumption levels at 3.79 oz/day for MAFLD and 3.87 oz/day for MU-MAFLD. Conclusions These insights accentuate the prospective protective effects of NUTSDS consumption against all-cause mortality in MAFLD individuals, especially salient in the MU-MAFLD demographic.

Publisher

Research Square Platform LLC

Reference50 articles.

1. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes;Younossi ZM;Hepatology,2016

2. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi Z;Nat Rev Gastroenterol Hepatol,2018

3. Non-alcoholic fatty liver disease – A global public health perspective;Younossi ZM;J Hepatol,2019

4. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement;Eslam M;J Hepatol,2020

5. Comparison of MAFLD and NAFLD diagnostic criteria in real world;Lin S;Liver Int,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3